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Abstract: Premature ejaculation (PE) is a common male sexual disorder. Recent normative 
data suggest that men with an intravaginal ejaculatory latency time (IELT) of less than 1 minute 
have “deﬁ  nite” PE, while men with IELTs between 1 and 1.5 minutes have “probable” PE. 
Although there is insufﬁ  cient empirical evidence to identify the etiology of PE, there is limited 
correlational evidence to suggest that men with PE have high levels of sexual anxiety and 
inherited altered sensitivity of central 5-HT (serotonin) receptors. Pharmacological modulation 
of the ejaculatory threshold using off-label daily or on-demand selective serotonin re-uptake 
inhibitors (SSRIs) offers patients a high likelihood of achieving improved ejaculatory control 
within a few days of initiating treatment, consequential improvements in sexual desire and 
other sexual domains and is well tolerated. Investigational drugs such as the ejaculo-selective 
serotonin transport inhibitors (ESSTIs) such as dapoxetine and UK-390,957 represent a major 
development in sexual medicine. These drugs offer patients the convenience of on-demand 
dosing, signiﬁ  cant improvements in IELT, ejaculatory control, and sexual satisfaction with 
minimal adverse effects.
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Introduction
Although premature ejaculation (PE) is one of the most common male sexual disorders 
and has been estimated to occur in 4%–39% of men in the general community, there 
is a lack of a universally accepted deﬁ  nition (Reading and Wiest 1984; Nathan 1986; 
Spector and Boyle 1986; Spector and Carey 1990; Grenier and Byers 1997; Laumann 
et al 1999; Rosen et al 2004). Medical literature contains several univariate and 
multivariate operational deﬁ  nitions of PE. The lack of agreement as to what constitutes 
PE has hampered basic and clinical research into the etiology and management of this 
condition. The World Health Organization (WHO) 2nd International Consultation 
on Sexual Health deﬁ  ned it as “... persistent or recurrent ejaculation with minimal 
stimulation before, on, or shortly after penetration, and before the person wishes it, 
over which the sufferer has little or no voluntary control which causes the sufferer 
and/or his partner bother or distress...” (Lue et al 2004). This multivariate deﬁ  nition 
encompasses the main dimensions of PE–ejaculatory latency, control, bother and 
sexual satisfaction.
Although PE may affect the level of sexual satisfaction of both men and/or their 
partners, few studies have examined the impact of PE on the man, his partner and/or their 
relationship (Rowland et al 2001; Byers and Grenier 2003). Many patients are reluctant 
to seek help and to discuss this issue with their physician out of embarrassment and 
uncertainty whether effective treatment options are available. In many relationships, 
PE causes few if any problems. Couples may reach an accommodation of the problem 
through various strategies – young men with a short refractory period may often 
experience a second and more controlled ejaculation during a subsequent episode of 
lovemaking. Frequently however, PE eventually leads to signiﬁ  cant relationship problems Neuropsychiatric Disease and Treatment 2006:2(4) 490
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with partners regarding the man as selﬁ  sh and developing a 
pattern of sexual avoidance. This only worsens the severity 
of the prematurity on the occasions when intercourse does 
occur.
Epidemiology
Most community-based epidemiological studies are limited 
by their use of either diagnosis by patient self-report of 
PE or inconsistent and poorly validated deﬁ  nitions of PE. 
Furthermore, subjective complaints of PE may have differing 
meanings in different cultures and the attitude of the partner 
and, in heterosexual relationships, her culturally determined 
extent of emancipation may impact upon the subjective 
patient’s diagnosis of PE.
A recent multinational community-based age-ranging 
study of an unselected “normal” population of 500 
heterosexual couples which involved stopwatch timing of the 
intravaginal ejaculatory latency time (IELT) during sexual 
intercourse has provided previously lacking normative data 
(Waldinger, Quinn, et al 2005). This study demonstrated 
that the distribution of the IELT was positively skewed, with 
a median IELT of 5.4 minutes (range, 0.55–44.1 minutes) 
(Figure 1). The median IELT decreased signiﬁ  cantly with age, 
from 6.5 minutes in the 18–30 years group, to 4.3 minutes in 
the group older than 51 years (p   0.0001). The median IELT 
varied between countries, with the median value for Turkey 
being the lowest, ie, 3.7 minutes (0.9–30.4 minutes), which 
was signiﬁ  cantly different from each of the other countries. 
The median IELT value was not affected by condom use 
or circumcision status. The authors regarded the 0.5 and 
2.5 percentiles as acceptable standards of disease deﬁ  nition in 
this type of skewed distribution, and proposed that men with 
an IELT of less than 1 minute (belonging to the 0.5 percentile) 
have “deﬁ  nite” PE, while men with IELTs between 1 and 
1.5 minutes (between 0.5 and 2.5 percentile) have “probable” 
PE (Waldinger, Zwinderman, et al 2005). Further community-
based large-scale international studies using the same meth-
odology but also exploring the dimensions of control, sexual 
satisfaction, and bother/distress are required to conﬁ  rm and 
expand upon these initial ﬁ  ndings.
There are few published data on impact of birth country, 
religion, or culture on the prevalence of PE. Anecdotally, PE 
is more commonly reported by adolescents or young adults. 
An increased susceptibility to PE in men from the Indian 
subcontinent has been reported (Bhatia and Malik 1991; 
Verma et al 1998). PE is more frequently reported by men 
in East Asia (China, Indonesia, Japan, Korea, and Malaysia), 
and less frequently by men in Middle Eastern and African 
countries (Algeria, Egypt, Morocco, and Turkey). However, 
a recent study reported a preponderance of men from Middle 
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Figure 1 Distribution of intravaginal ejaculatory latency times (IELT) values in a random cohort of 491 men. Reprinted with permission from Waldinger MD, Quinn P, 
Dilleen M, et al. 2005. A multinational population survey of intravaginal ejaculation latency time.  J Sex Med, 2:492–7.  © 2005 Blackwell Publishing.Neuropsychiatric Disease and Treatment 2006:2(4) 491
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Eastern and Asian backgrounds living in the United King-
dom presenting for treatment of PE which exceeded the 
representation of these ethnic groups in the local population 
(Richardson and Goldmeier 2005). The demonstrated vari-
ance in IELT between countries may be related to genetic 
or sociocultural factors but additional studies are required 
to conﬁ  rm these ﬁ  ndings.
The premise that PE is a psychosomatic disturbance and 
due to a psychologically overanxious personality was ﬁ  rst 
suggested by Schapiro in 1943. He classiﬁ  ed PE as either 
primary (lifelong) or secondary (acquired) (Schapiro 1943). 
The behavioristic view that chronic PE was the result of 
performance anxiety related to a disturbing initial episode 
of PE was ﬁ  rst proposed by Masters and Johnson (1966). 
Most of the behavioral treatments currently used are based 
on this premise.
In a study of 1326 consecutive men with PE, lifelong 
PE was present in 736 men (74.4%) and acquired PE was 
present in 253 men (25.6%) (McMahon 2002). Men with 
PE appear younger than those without, and after adjusting 
for concomitant erectile dysfunction (ED) the risk of PE 
significantly decreased with aging (Fasolo, Mirone, et al 
2005). Higher levels of education and divorce appear to 
increase the risk of PE. A decreased risk of PE has been 
reported in men with treated diabetes, and no association 
was found with hypertension, cardiac disease, hypercho-
lesterolemia, and peripheral or central neuropathy. Men 
with self-reported PE have a lower frequency of sexual 
intercourse, higher levels of intercourse-related anxiety, 
and note greater impairment in intercourse satisfaction, 
and sexual relationship satisfaction compared to men 
without PE (Perelman et al 2004). However, they do not 
report a reduced quality of life, reduced sexual desire or 
a reduced ability to become sexually aroused (Lue et al 
2004; Perelman et al 2004).
Over the past 15 years, an increasing number of 
publications have reported the pharmacological treatment 
of PE with a variety of different medications, which act 
centrally or locally to retard the psycho-neurological 
control of ejaculation and subsequent orgasm (Montague 
et al 2004). It is well established that major tranquillizers 
and selective serotonin re-uptake inhibitor drugs (SSRIs) 
retard ejaculation significantly and will, in a small 
percentage of men, result in an ejaculation (Kotin et al 
1976; Monteiro 1987; Deveaugh-Geiss 1989). The 
efficacy of SSRIs in delaying ejaculation combined with 
the low side-effect profile make them first-line agents 
for PE administered either on a daily or an “on-demand 
basis” (Waldinger, Hengeveld, et al 1998b; McMahon 
and Touma 1999).
Physiology of ejaculation
Ejaculation is a reflex comprising sensory receptors 
and areas, afferent pathways, cerebral sensory areas, 
cerebral motor centers, spinal motor centers, and efferent 
pathways. There are three basic mechanisms involved 
in normal antegrade ejaculation – emission, ejection, 
and orgasm (Lipshultz et al 1981). Emission is the result 
of a sympathetic spinal cord reﬂ  ex initiated by genital 
and/or cerebral erotic stimuli and involves the sequential 
contraction of accessory sexual organs. Considerable initial 
voluntary control of emission progressively decreases 
until the point of ejaculatory inevitability (Yeates 1987). 
Ejection also involves a sympathetic spinal cord reﬂ  ex 
upon which there is little or no voluntary control. Ejection 
involves bladder neck closure, rhythmic contractions of 
bulbocavernous, bulbospongiosus and other pelvic ﬂ  oor 
muscles, and relaxation of the external urinary sphincter 
(Yeates 1987). Orgasm is the result of cerebral processing 
of pudendal nerve sensory stimuli resulting from increased 
pressure in the posterior urethra, sensory stimuli arising 
from the veramontanum, and contraction of the urethral 
bulb and accessory sexual organs.
The ejaculatory reflex is predominantly controlled 
by a complex interplay between central serotonergic and 
dopaminergic neurons with secondary involvement of 
cholinergic, adrenergic, nitrergic, oxytocinergic, galanergic, 
and GABAergic neurons. The cerebral events which occur 
during ejaculation and the abnormalities present in men 
with PE have not been clearly deﬁ  ned with PET and fMRI 
brain imaging techniques. Seminal emission and ejection are 
integrated into the complex pattern of copulatory behavior 
by several forebrain structures including the medial preoptic 
area (MPOA) and the nucleus paragigantocellularis (nPGi) 
(Robinson and Mishkin 1966; Yells et al 1992). Descending 
serotonergic pathways from the nPGI to the lumbosacral 
motor nuclei tonically inhibit ejaculation (Yells et al 
1992). Disinhibition of the nPGI by the MPOA facilitates 
ejaculation. A population of lumbar spinothalamic neurons 
has been identiﬁ  ed in male rats (LSt cells) that constitutes 
an integral part of the generation of ejaculation. LSt 
cells send projections to the autonomic nuclei and motor 
neurons involved in the emission and expulsion phase, and 
they receive sensory projections from the pelvis (Truitt 
and Coolen 2002). Several brain areas are activated after 
ejaculation by ascending ﬁ  bers from the spinal cord and Neuropsychiatric Disease and Treatment 2006:2(4) 492
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may have a possible role in satiety and the post-ejaculatory 
refractory time.
Our understanding of the neurobiology of both normal 
ejaculation and ejaculatory dysfunction, the supraspinal and 
spinal neuroanatomical pathways (Pfaus and Heeb 1997; 
Veening and Coolen 1998; Truitt and Coolen 2002; Truitt 
et al 2003), and the multiple brain neurotransmitters and/or 
neuropeptides involved has evolved as a result of several 
animal studies where the sexual behavior of laboratory 
rats was investigated during pharmacological challenge 
and/or stimulation of speciﬁ  c brain areas (Larsson and 
Ahlenius 1999; Pfaus 1999). These studies have attributed 
a serotonergic basis and possible genetic etiology to PE 
(Olivier et al 1998; Waldinger, Rietschel, et al 1998; 
Waldinger and Hengeveld 2000; Waldinger and Olivier 
2001). Male rat studies demonstrate that serotonin and 5-HT 
receptors are involved in the ejaculatory process. The speed 
of ejaculation appears to be determined by 5-HT2C and 
5-HT1A receptors. Stimulation of 5-HT2C receptors with 
non-selective 5-HT2C agonists delays ejaculation in male 
rats whereas stimulation of postsynaptic 5-HT1A receptors 
resulted in shorter ejaculation latency (Ahlenius et al 1981). 
Administration of SSRIs results in active blockade of 
presynaptic membrane 5-HT transporters, and the resultant 
higher synaptic cleft levels of 5-HT activate post-synaptic 
5-HT2C and 5-HT1A receptors and delay ejaculation (Olivier 
et al 1998; Waldinger, Berendsen et al 1998).
Diagnosis
Diagnosis of PE in clinical practice is not difﬁ  cult and is 
based on patient self-report, clinical history, and examination 
ﬁ  ndings alone. Men with PE should be evaluated with a 
detailed medical and sexual history, a physical examination 
and appropriate investigations to establish the true presenting 
complaint and identify any obvious biological causes 
such as genital or lower urinary tract infection. However, 
treating physicians must interpret patient self-report of PE 
with some caution as the estimation of ejaculatory latency 
by men and women may correlate poorly with stopwatch 
measured latency times. It is clinically relevant to distinguish 
lifelong and acquired PE. Usually lifelong PE has a global 
manifestation whereas acquired PE may occur situationally 
(Grenier and Byers 1992).
However in a research setting, objective measurement 
of the intravaginal ejaculatory latency time (IELT) by stop-
watch and subjectively validated, reliable and consistent 
patient reported outcome measures (PROs) of ejaculatory 
control, sexual satisfaction, and bother/distress are essential 
(Symonds et al 2002; Rust and Golombok 1986; Yuan et al 
2004). Each of the three criteria above has been operationalized, 
although not always with consistency (Rowland et al 2001). 
Clinical trial outcome measures include the following.
Intravaginal ejaculatory latency time 
(IELT)
The length of time between penetration and ejaculation, 
the IELT forms the basis of most current clinical studies 
on PE (Waldinger et al 2004). The IELT is measured with 
a stopwatch operated by the female partner, is expressed 
in seconds or minutes, and in case of ante-portal ejacula-
tion, is equal to zero. Waldinger et al reported IELTs of 
less than 30 seconds and less than 60 seconds in 77% 
and 90% of 110 men with PE, respectively (Waldinger, 
Hengeveld, et al 1998a). McMahon et al reported similar 
results in 1346 consecutive men with PE and a mean IELT 
of 43.4 seconds (McMahon 2002). Predominant ante-portal 
ejaculation (during foreplay) occurred in 5.6% of men. How-
ever, recent normative data derived from a multinational, 
community-based, age-ranging study have provided previ-
ously lacking normative data suggesting that men with IELTs 
of less than 60 seconds and between 60 and 90 seconds have 
“deﬁ  nite” PE and “probable” PE, respectively (Waldinger, 
Quinn, et al 2005).
Voluntary control
Kaplan and other authors have suggested that an inability to 
voluntarily defer ejaculation deﬁ  nes PE (Kaplan et al 1974; 
Zilbergeld 1978; Vandereycken 1986; McCarthy 1988). This 
deﬁ  nition has yet to be adequately operationalized to allow 
comparison across subjects or across studies (Grenier and 
Byers 1997; Waldinger, Hengeveld, et al 1998a; Patrick, 
Althof, et al 2005). Patrick et al reported ratings of “very 
poor” or “poor” for control over ejaculation in 72% of men 
with PE compared with 5% in a group of normal controls 
(Patrick et al 2005). The patient’s feeling of ejaculatory 
control is a subjective measure and difﬁ  cult to translate in 
quantiﬁ  able terms. Although feelings of ejaculatory control 
are part of the ejaculation process, diminished feelings of 
ejaculatory control are not exclusive for men suffering from 
PE and some men with a brief IELT report adequate ejacula-
tory control (Grenier and Byers 1997).
Sexual satisfaction
Men with PE report lower levels of sexual satisfaction than do 
men with normal ejaculatory latency. A recent observational 
study reported sexual satisfaction ratings of “very poor” or Neuropsychiatric Disease and Treatment 2006:2(4) 493
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“poor” in 31% of men with PE, compared with 1% in a group 
of normal controls (Patrick et al 2005).
Distress
Existing deﬁ  nitions of PE include distress as an important 
dimension of PE (APA 1994; Lue et al 2004; Montague et al 
2004). However, the word “distress” has negative social 
implications and its existence is denied by most men with 
PE. This dimension of PE is better captured by the word 
“bother.” The extent of bother deﬁ  nes the severity of PE. 
One study reported that 64% of men with PE rated their 
extent of personal distress as “quite a bit” or “extremely” 
compared to 4% in a group of normal controls (Patrick et al 
2005). Although partner distress is perhaps the most common 
reason for men with PE to seek treatment, there is limited 
information regarding the effect of PE on the partner. Patrick 
et al reported that 44% of partners of men with PE rated their 
extent of personal distress as “quite a bit” or “extremely” 
compared to 3% in a group of partners of normal controls 
(Patrick et al 2005).
The results of PE drug clinical trials are only reliable, 
interpretable, and capable of being generalized to patients 
with the disorder studied when conducted in well-
deﬁ  ned and consistent populations, using a double-blind, 
placebo-controlled study design with consistent objective 
physiological measures or sensitive, validated outcome 
assessment instruments as study endpoints (Lue et al 
2004). The dimensions of latency, control, satisfaction, 
and distress/bother must be well-deﬁ  ned, measured, and 
analyzed as continuous variables without arbitrary cut-off 
values. Subjective patient reported outcomes (PROs) of 
ejaculatory control, sexual satisfaction and bother/distress 
may be important additional efﬁ  cacy endpoints and can 
be evaluated using validated patient reported outcome 
instruments (Symonds et al; Rust and Golombok 1986; 
Yuan, Xin et al 2004). However, a meta-analysis of 35 drug 
treatment studies has conﬁ  rmed that the variability of answers 
of spontaneous reports and questionnaire studies on the 
IELT are signiﬁ  cantly higher than stopwatch assessments 
(Waldinger, Zwinderman, et al 2004).
Etiology of premature ejaculation
Historically, attempts to explain the etiology of PE has 
included a diverse range of biological and psychological theo-
ries. Most of these proposed etiologies are not evidence-based 
and are speculative at best. Psychological theories include 
the effect of early experience and sexual conditioning, 
anxiety, sexual technique, the frequency of sexual activity, 
and psychodynamic explanations. Biological explanations 
include evolutionary theories, penile hypersensitivity, central 
neurotransmitter levels and receptor sensitivity, degree of 
arousability, the speed of the ejaculatory reﬂ  ex, and the level 
of sex hormones.
There is little empirical evidence to suggest a causal 
link between PE and any of the factors thought to cause PE. 
There is, however, limited correlational evidence to suggest 
that lifelong PE is due to altered sensitivity of central 5-HT 
receptors and acquired PE is due to high levels of sexual 
anxiety, ED or lower urinary tract infection.
Ejaculatory latency time is probably a biological variable, 
which is genetically determined and may differ between 
populations and cultures, ranging from “extremely rapid” 
through “average to slow” ejaculation. Hyposensitivity of 
the 5-HT2C and/or hypersensitivity of the 5-HT1A receptors 
have been suggested as a possible explanation of lifelong PE 
(Waldinger, Berendsen et al 1998; Waldinger 2002). Men 
with low 5-HT neurotransmission and probable 5-HT2C 
receptor hyposensitivity may have their ejaculatory threshold 
genetically “set” at a lower point and ejaculate quickly and 
with minimal stimulation whereas men with a higher set-
point men can sustain more prolonged and higher levels of 
sexual stimulation and can exert more control over ejacula-
tion. Men with a very high set-point may experience delayed 
or absent ejaculation despite achieving a full erection and 
prolonged sexual stimulation. Treatment with an SSRI class 
drug activates the 5-HT2C receptor, elevates the ejaculatory 
threshold set-point and delays ejaculation. The extent of 
ejaculatory delay may vary widely in different men according 
to the dosage and frequency of administration of SSRI and 
the genetically determined ejaculatory threshold set-point. 
Cessation of treatment results in re-establishment of the 
previous set-point within 5–7 days in men with lifelong PE.
Anxiety has been reported as a cause of PE by multiple 
authors and is entrenched in the folklore of sexual medicine 
as the most likely cause of PE despite scant empirical 
research evidence to support any causal role (Schapiro 1943; 
Kaplan et al 1974; Williams 1984). Several authors have 
suggested that anxiety activates the sympathetic nervous 
system and reduces the ejaculatory threshold as a result 
of an earlier emission phase of ejaculation (Kaplan et al 
1974; Williams 1984). The possibility that high levels of 
anxiety, and excessive and controlling concerns about sexual 
performance and potential sexual failure might distract a man 
from monitoring his level of arousal and recognizing the 
prodromal sensations that precede ejaculatory inevitability, 
has been suggested as a possible cause of PE by several Neuropsychiatric Disease and Treatment 2006:2(4) 494
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authors (Zilbergeld 1978; Kockott et al 1980; Kaplan 1983; 
Vandereycken 1986; Kaplan 1989; Zilbergeld 1992). The 
causal link between anxiety and PE is speculative, is not 
supported by any empirical evidence and is, in fact, contrary 
to empirical evidence from some researchers (Strassberg 
et al 1990).
Recent data demonstrate that almost half of men with 
ED also experience PE (Laumann et al 2005). Men with 
early ED may intentionally “rush” sexual intercourse to 
prevent premature loss of their erection and ejaculate with 
a brief latency. This may be compounded by the presence 
of high levels of performance anxiety related to their 
ED which serves only to worsen their prematurity. In 
the absence of a thorough sexual history, these men may 
be incorrectly diagnosed as suffering from PE and not the 
underlying ED.
Pharmacological treatment
Pharmacological modulation of ejaculatory threshold 
represents a novel and refreshing approach to the treatment 
of PE and a radical departure from the psychosexual model, 
previously regarded as the cornerstone of treatment. The 
introduction of the selective serotonin reuptake inhibitors 
SSRIs has revolutionized the approach to and treatment 
of PE. SSRIs encompass five compounds: citalopram, 
ﬂ  uoxetine, ﬂ  uvoxamine, paroxetine, and sertraline, with a 
similar pharmacological mechanism of action. Although 
the methodology of the initial drug treatment studies was 
rather poor, later double-blind and placebo-controlled studies 
replicated the genuine effect of clomipramine and SSRIs 
to delay ejaculation. In spite of a development towards 
more evidence-based drug treatment research, the majority 
of studies still lack adequate design and methodology 
(Waldinger 2003). A recent meta-analysis of all drug 
treatment studies demonstrated that only 14.4% had been 
performed according to the established criteria of evidence-
based medicine, and that open design studies and studies 
using subjective reporting or questionnaires showed a higher 
variability in ejaculation delay than double-blind studies in 
which the ejaculation delay was prospectively assessed with 
a stopwatch (Waldinger 2003).
Daily treatment with SSRIs
Daily treatment can be performed with paroxetine 
20–40 mg, clomipramine 10–50 mg, sertraline 50–100 mg, 
and ﬂ  uoxetine 20–40 mg. Paroxetine appears to exert the 
strongest ejaculation delay, increasing IELT approximately 
8.8 fold over baseline (Waldinger 2003). Ejaculation delay 
usually occurs within 5–10 days but may occur earlier 
(Figure 2) (McMahon 1998). Adverse effects are usually 
minor, start in the first week of treatment, gradually 
disappear within 2–3 weeks and include fatigue, yawning, 
mild nausea, loose stools or perspiration. Diminished libido 
or mild ED is infrequently reported. Signiﬁ  cant agitation is 
reported by a small number of patients and treatment with 
SSRIs should be avoided in men with a history of bipolar 
depression.
On-demand treatment with SSRIs
Administration of clomipramine, paroxetine, sertraline, 
fluoxetine 4–6 hours before intercourse is efficacious 
and well-tolerated but is associated with less ejaculatory 
delay than daily treatment. Daily administration of an 
SSRI is associated with superior fold increases in IELT 
compared with on-demand administration due to greatly 
enhanced 5-HT neurotransmission resulting from several 
adaptive processes which may include presynaptic 5-HT1a 
and 5-HT1b/1d receptor desensitization (Figure 3) 
(Waldinger, Berendsen, et al 1998). On-demand treatment 
may be combined with either an initial trial of daily 
treatment or concomitant low dose daily treatment (Kim 
and Paick 1999; McMahon and Touma 1999; Strassberg 
et al 1999).
Ejaculo-selective serotonin 
transport inhibitors (ESSTIs)
A number of rapid-acting short half-life SSRIs (dapoxetine, 
Johnson & Johnson, UK-390, 957-Pfizer) are under 
investigation as on-demand treatments for PE.
Dapoxetine
Dapoxetine is the ﬁ  rst compound speciﬁ  cally developed for the 
treatment of PE. Dapoxetine is a potent SSRI (pKi  =  8 nM), 
structurally similar to ﬂ  uoxetine (Figure 4) (Sorbera et al 
2004). Equilibrium radioligand binding studies using human 
cells demonstrate that dapoxetine binds to 5-HT, norepi-
nephrine (NE) and dopamine (DA) re-uptake transporters 
and inhibits uptake in the following rank order of potency: 
NE   5-HT    DA (Gengo et al 2005). Brain PET studies 
have demonstrated significant displaceable binding of 
radiolabeled dapoxetine in the cerebral cortex and subcortical 
grey matter (Livni et al 1994).
Pharmacokinetics
Dapoxetine undergoes rapid absorption and elimination 
resulting in minimal accumulation and has dose-proportional Neuropsychiatric Disease and Treatment 2006:2(4) 495
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pharmacokinetics, which are unaffected by multiple dosing 
(Figure 5). The pharmacokinetic proﬁ  le of dapoxetine suggest 
that it is a good candidate for on-demand treatment of PE. 
The pharmacokinetics of both single doses and multiple doses 
over 6–9 days (30, 60, 100, 140, or 160 mg) of dapoxetine 
were been evaluated.
In a randomized, double-blind, placebo-controlled trial, 
single doses and multiple doses over 6 days of dapoxetine 
(60, 100, 140, or 160 mg) were administered to 77 healthy 
male volunteers (Dresser, Lindert, et al 2004). Dapoxetine 
has a Tmax of 1.4–2.0 hours and rapidly achieves peak 
plasma concentration (Cmax) following oral administration. 
Both plasma concentration and area under the curve (AUC) 
are dose dependent up to 100 mg. The mean half-life of 
dapoxetine after a single dose is 0.5–0.8 hours and plasma 
concentrations rapidly decline to about 5% of Cmax at 
24 hours. The terminal half-life of dapoxetine was 15–19 
hours after a single dose and 20–24 after multiple doses.
In a subsequent pharmacokinetic study, single doses and 
multiple doses over 9 days of dapoxetine (30, 60 mg) were 
evaluated in a randomized, open-label, 2-treatment, 2-period, 
crossover study of 42 healthy male volunteers (Modi et al 
2005a). Subjects received a single dose of dapoxetine 30 mg 
on Day 1 (single-dose phase) and on Days 4–9 (multiple-dose 
phase); and a single dose of dapoxetine 60 mg on Day 1 and on 
Days 4–9. Dapoxetine was rapidly absorbed, with mean maxi-
mal plasma concentrations of 297 and 349 ng/mL noted 1.01 
and 1.27 hours after single doses of dapoxetine 30 and 60 mg, 
respectively (Table 1). Elimination of dapoxetine was rapid 
and biphasic, with an initial half-life of 1.31 and 1.42 hours, 
and a terminal half-life of 18.7 and 21.9 hours following single 
doses of dapoxetine 30 and 60 mg, respectively. The pharma-
cokinetics of dapoxetine and its metabolites were not affected 
by repeated daily dosing and state plasma concentrations 
were reached within 4 days, with only modest accumulation 
of dapoxetine (approximately 1.5 fold).
Food does not have a clinically signiﬁ  cant effect on 
dapoxetine pharmacokinetics. Mean maximal plasma 
concentrations of dapoxetine decrease slightly after a high-
fat meal, from 443 ng/mL (fasted) to 398 ng/mL (fed), and 
are delayed by approximately 0.5 hours following a high-fat 
meal (1.30 hours fasted, 1.83 hours fed) (Dresser, Modi, et al 
2005). The rate of absorption is modestly decreased, but there 
is no effect of food on the elimination of dapoxetine or the 
exposure to dapoxetine, assessed by the area under the plasma 
concentration-versus-time curve (AUC). The frequency of 
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Figure 2 Selective serotonin re-uptake inhibitors produce ejaculatory delay within 5–10 days (McMahon 1998).Neuropsychiatric Disease and Treatment 2006:2(4) 496
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nausea is decreased after a high-fat meal (24% [7/29] of fasted 
subjects and 14% [4/29] of fed subjects, respectively).
Dapoxetine is extensively metabolized to multiple 
metabolites including desmethyldapoxetine, didesmethyl-
dapoxetine, and dapoxetine-N-oxide, all of which have much 
lower plasma concentrations compared with dapoxetine 
(Dresser et al 2004). Details of the speciﬁ  c pathways and 
isoenzymes involved in metabolism, the volume of drug 
distribution and details on excretion are not currently avail-
able (Dresser et al 2004).
Animal studies
Animal studies using rat experimental models have 
demonstrated that acute treatment with oral, subcutaneous, 
and IV dapoxetine inhibits ejaculation at doses as low as 
1 mg/kg.
Clement et al reported the effects of IV dapoxetine on 
the emission and expulsion phases of ejaculation using 
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Figure 3 A. Synaptic cleft 5-HT and 5-HT neurotransmission are regulated by somatodendritic 5-HT1A autoreceptors, presynaptic 5-HT1B/1D autoreceptors and a 5-HT 
transporters re-uptake system. As 5-HT is released into the synaptic cleft from pre-synaptic axonal vesicles, 5-HT transporters re-uptake and remove 5-HT from the 
synaptic cleft, preventing over-stimulation of the postsynaptic receptors. B. After blockage of 5-HT transporters by acute administration of selective serotonin re-uptake 
inhibitor class drugs (SSRIs) synaptic cleft 5-HT increases but is counteracted by activation of 5-HT1A autoreceptors which inhibit further 5-HT release. C. Chronic 
administration of selective serotonin re-uptake inhibitor class drugs (SSRIs) results in greatly enhanced 5-HT neurotransmission due to several adaptive processes which 
may include presynaptic 5-HT1A and 5-HT1B/1D receptor desensitisation (Olivier et al 1998).
N
O
HCl
Figure 4 Molecular structure of dapoxetine: (+)-(S)-N, N-dimethyl-(α)-[2(1naphtha
lenyloxy)ethyl]-benzenemethanamine hydrochloride.
p-chloroamphetamine (PCA)-induced ejaculation as an 
experimental model of ejaculation in anesthetized rats 
(Clement et al 2006). Intraseminal vesicle pressure (SVP) and 
electromyograms of bulbospongiosus muscles (BS) were used 
as physiologic markers of the emission and expulsion phases, 
respectively. At all doses, dapoxetine signiﬁ  cantly reduced 
the proportion of rats displaying PCA-induced ejaculation in 
a dose-dependent manner, from 78% of rats with vehicle to Neuropsychiatric Disease and Treatment 2006:2(4) 497
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33%, 22%, and 13% of rats following IV dapoxetine 1, 3, and 
10 mg/kg, respectively. Dapoxetine signiﬁ  cantly decreased 
the AUC of PCA-induced SVP increases and BS contractile 
bursts by 78% at all doses, and by 91% following dapoxetine 
1 mg, respectively.
Using a different animal experimental model of the 
ejaculatory reﬂ  ex in rats, Giuliano et al measured the latency, 
amplitude and duration of pudendal motoneuron reflex 
discharges (PMRD) elicited by stimulation of the dorsal nerve 
of the penis before and after IV injection of vehicle, dapoxetine 
or paroxetine (1, 3, and 10 mg/kg) (Giuliano et al 2006). At the 
3 doses of dapoxetine tested, the latency of PMRD following 
stimulation of dorsal nerve of the penis was signiﬁ  cantly 
increased and the amplitude and duration of PMRD decreased 
from baseline values (Figure 6). Acute IV paroxetine appeared 
less effective than dapoxetine.
In a behavioral study of sexually experienced rats, Gengo 
et al reported that treatment with subcutaneous or oral dapox-
etine significantly delayed ejaculation compared to saline 
control (16 ± 4 min (subcut.) vs 10 ± 1 min. In saline controls, 
p   0.05) when administered 15, but not 60 or 180 minutes prior 
to exposure to receptive females (Figure 7) (Gengo et al 2006). 
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The greatest delay in ejaculatory latency was observed in 
animals with shorter baseline latencies and oral dapoxetine did 
not affect the latency in rats with a baseline latency longer than 
10 minutes.
Human clinical trials
The results of two phase 2 and two phase 3 trials have been 
published in abstract form.
Dapoxetine dose-finding data have been derived from 
two multicenter Phase 2 studies and used to determine 
the appropriate doses for Phase 3 studies. Both studies 
used a randomized, placebo-controlled, double-blind, 
3-period, crossover study design and randomized 
heterosexual men with PE diagnosed according to 
DSM-IV criteria and a baseline IELT of  2 minutes. 
Study drug was administered 1–2 hours prior to planned 
sexual intercourse activity and subjects were required to 
attempt intercourse at least twice a week. The primary 
outcome measure was IELT measured by partner-oper-
ated stopwatch.
In study 1 128 of 157 randomized subjects completed 
the study (Hellstrom et al 2005). Subjects were randomized 
to receive dapoxetine 20 mg, dapoxetine 40 mg, or placebo 
for 4 weeks with no washout period between treatment arms. 
Baseline IELT (mean baseline ILET = 1.34 min) was esti-
mated by patient recall. In study 2 130 of 166 randomized 
subjects completed the study (Hellstrom et al 2004). Subjects 
were randomized to receive dapoxetine 60 mg, dapoxetine 
100 mg, or placebo for 2 weeks, separated by a 3-day washout 
period. Baseline IELT (mean baseline IELT = 1.01 min) was 
measured by partner-operated stopwatch.
The intention-to-treat analysis of both studies demonstrated 
that all four doses of dapoxetine are effective, superior to 
placebo and increased IELT 2.0–3.2 fold over baseline 
in a dose-dependent fashion (Table 2) (Hellstrom et al 
2004; Hellstrom et al 2005). The magnitude of effect of 
dapoxetine 20 mg on IELT was small. The most commonly 
reported adverse events were nausea, diarrhea, headache, 
dizziness. The incidence of most adverse events appeared 
to be dose-dependent. The most common adverse event was 
nausea and occurred in 0.7%, 5.6%, and 16.1% of subjects 
with placebo, dapoxetine 60 mg and dapoxetine 100 mg, 
respectively. Overall, dapoxetine 60 mg was better tolerated 
than dapoxetine 100 mg. The most common reason for study 
withdrawal was nausea in patients receiving dapoxetine 
100 mg. Based on these results, doses of 30 mg and 60 mg 
were chosen for further investigation in Phase 3 efﬁ  cacy 
and safety studies.
In two Phase 3 multicenter studies using a randomized, 
placebo-controlled, double-blind study design, Pryor et al 
evaluated the efﬁ  cacy and safety of dapoxetine 30 mg and 
dapoxetine 60 mg in 2614 men diagnosed with PE according 
Table 1 Pharmacokinetics of single doses of dapoxetine 
(30, 60 mg) and effect of food on pharmacokinetics.
Dapoxetine 
30 mg
Dapoxetine 
60 mg
Cmax (ng/ml) 297a 349a
Tmax (h) 1.01a 1.27a
Initial T1/2 (h) 1.31a 1.42a
Terminal T1/2 (h) 18.7a 21.0a
Effect of high fat meal
Cmax (fasted) − 443b
Cmax (high fat meal) − 398b
Tmax (h) (fasted) − 1.30b
Tmax (h) (high fat meal) − 1.83b
(aModi et al 2005b; bDresser, Modi, et al 2005).
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Figure 6 The latency, amplitude and duration of pudendal motoneuron reﬂ  ex 
discharges (PMRD) elicited by stimulation of the dorsal nerve of the penis in a 
rat esperimental model of ejaculation before and after IV injection of vehicle, 
dapoxetine or paroxetine (1, 3, and 10 mg/kg). (***p   0.001, *p   0.05 compared 
to vehicle) (Giuliano et al 2006).
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Figure 7 Ejaculatory latency in male rats that received dapoxetine 35 mg/kg, 15 to 
180 minutes before testing (Gengo et al 2006).Neuropsychiatric Disease and Treatment 2006:2(4) 499
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to DSM-IV criteria and a baseline IELT of  2 minutes (Pryor 
et al 2005). Following a 2 week baseline run-in period, 
patients were randomized to receive 12 weeks treatment 
with either dapoxetine 30 mg, dapoxetine 60 mg, or placebo. 
Study drug was administered 1–3 hours prior to planned 
sexual intercourse activity. The primary outcome measure 
was IELT measured by partner-operated stopwatch and 
secondary outcome measures included the patient reported 
outcomes (PROs) of perception of Control over Ejaculation 
and perception of Satisfaction with Sexual Intercourse using 
a 5-point scoring scale (0 = very poor to 5 = very good).
In both studies, dapoxetine (30/60 mg) signiﬁ  cantly 
improved primary and secondary outcome measures 
compared to placebo (Figure 8). Of signiﬁ  cance was the 
report that dapoxetine (30/60 mg) was more effective than 
placebo in increasing IELT on the initial dose and maintained 
that efﬁ  cacy with subsequent dosing (Figure 9). Intravaginal 
ejaculatory latency time (IELT) increased from 0.91 minutes 
at baseline to 2.78 and 3.32 minutes at study end with dapox-
etine 30 and 60 mg, respectively. In comparison, the placebo 
group increased from a baseline of 0.90–1.75 minutes.
Mean patient rating of Control Over Ejaculation as fair, good, 
or very good increased from 2.8% at baseline to 51.8% and 58.4% 
at study end with dapoxetine 30 and 60 mg, respectively. Similar 
results were seen with Satisfaction of Sexual Intercourse with 
changes from baseline of 52.4%– 70.9% with dapoxetine 30 mg, 
56.7% to 79.2% with dapoxetine 60 mg, and 51.8%–55.2% with 
placebo (Figure 8).
Treatment-related side–effects were uncommon, dose 
dependent, included nausea, diarrhea, headache, and dizzi-
ness, and were responsible for study discontinuation in 4% 
(30 mg) and 9.5% (60 mg) of subjects. Nausea and headache 
were the most common adverse events reported with both 
doses of dapoxetine. Nausea was reported by 1.9%, 8.7%, and 
20.1% of patients with placebo, dapoxetine 30 mg group and 
Table 2 Results of dapoxetine Phase 2 studies (Hellstrom et al 2004; Hellstrom et al 2005).
Study 1 Study 2
Age range (years) 18–60
 2 min estimated
4 wk per treatment
None
18–65
 2 min by stopwatch
2 wks per treatment
72 h
Inclusion IELT
Treatment period
Washout period
Dapoxetine dose 20 mg
(n = 145)
40 mg
(n = 141)
Placebo
(n = 142)
60 mg
(n = 144)
100 mg
(n = 155)
Placebo
(n = 145)
Mean baseline IELT 1.34 1.34 1.34 1.01 1.01 1.01
Mean Treatment IELT 2.72* 3.31† 2.22 2.86† 3.24† 2.07
IELT fold increase 2.0 2.5 1.7 2.9 3.2 2.0
Discontinuation due to 
AE
020091
*p = 0.042, †p   0.0001 vs placebo.
0.9 0.92 0.91
1.75 
2.78*
3.32**
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Placebo
Placebo
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Figure 8 A. Dapoxetine increased intravaginal ejaculatory latency time (IELT) from 
0.91 minutes at baseline to 2.78 and 3.32 minutes at study end with dapoxetine 
30 and 60 mg respectively. B. % of subjects rating Control Over Ejaculation as fair, 
good, or very good increased from 3.1% at baseline to 51.8% and 58.4% at study 
end with dapoxetine 30 and 60 mg respectively. C. % of subjects rating Sexual 
Satisfaction as fair, good or very good increased from 53.6% at baseline to 70.9% 
and 79.2 % with dapoxetine 30 mg and 60 mg respectively (rating scale 0–5 scale, 
0 = very poor, and 5 = very good) (Pryor et al 2005).
dapoxetine 60 mg. Headache was reported by 4.0%, 5.9%, 
and 6.8% of patients with placebo, dapoxetine 30 mg and 
dapoxetine 60 mg, respectively. Diarrhea and dizziness were 
also more common with dapoxetine 60 mg compared with 
placebo and dapoxetine 60 mg, occurring in 6.8% and 6.2% of 
subjects. Erectile dysfunction was reported by 2.9% and 3.8% 
of subjects taking dapoxetine 30 mg and dapoxetine 60 mg.Neuropsychiatric Disease and Treatment 2006:2(4) 500
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Although no direct comparator trials of dapoxetine and 
other SSRIs have been reported, daily administration of par-
oxetine is likely to produce a greater fold increase in IELT 
than on-demand dapoxetine due to the greatly enhanced 5-HT 
neurotransmission resulting from several adaptive processes 
in the serotonergic neuron which occur with daily dosing 
(Table 3) (Waldinger, Berendsen, et al 1998).
Adverse effects
The most common adverse events seen in Phase 2 and 3 
trials of dapoxetine of were nausea, headache, diarrhea, 
and dizziness and were dose-dependent (Hellstrom et al 
2004; Pryor et al 2005). Although nausea was reported by 
20.1% of subjects taking dapoxetine 60 mg, its incidence 
attenuated with continued use and its severity was assessed 
as mild by most patients with vomiting occurring in only 
2.2% of subjects with this dose. Overall, 6.7% of subjects 
discontinued dapoxetine due to adverse events, predominantly 
nausea. There are currently no reports of any cardiovascular, 
hepatic, renal or hematological adverse events associated 
with dapoxetine.
Drug interactions
No drug–drug interactions associated with dapoxetine 
have been reported. Co-administration of dapoxetine with 
ethanol did not produce signiﬁ  cant changes in dapoxetine 
pharmacokinetics (Modi, et al 2005). Mean peak plasma 
concentrations of dapoxetine, its metabolites and ethanol 
did not signiﬁ  cantly change with co-administration and 
there were no clinically signiﬁ  cant changes in ECGs, clini-
cal laboratory results, physical examination and no serious 
adverse events. Drug interactions studies demonstrate 
that tadalaﬁ  l, a phosphodiesterase-5 inhibitors used in the 
treatment of ED, did not affect the pharmacokinetics of 
dapoxetine, whereas sildenaﬁ  l increased the dapoxetine 
AUC by 22% (Dresser, Jazrawi, et al 2005). However, 
this was not regarded as clinically important. Dapoxetine 
did not appear to affect the pharmacokinetics of tadalaﬁ  l 
or sildenaﬁ  l.
Dosage and administration
Large Phase 3 studies demonstrate that doses of 30 mg and 
60 mg administered on-demand 1 to 3 hours before planned 
sexual intercourse are appropriate for clinical use.
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Figure 9 Dapoxetine (30/60 mg) was more effective than placebo in increasing 
IELT on the initial dose and maintained that efﬁ  cacy with subsequent dosing (Pryor 
et al 2005).
Table 3 Comparison of fold increases in IELT with meta-analysis data for daily paroxetine, sertraline, ﬂ  uoxetine, clompipramine 
(Waldinger, Zwinderman, et al 2004) and phase 3 data for on-demand dapoxetine (Pryor et al 2005).
Drug Regulatory 
approval
Dose Mean fold 
increase 
in IELT
Selective serotonin reuptake inhibitor (SSRIs)
Paroxetine (Paxil®, GlaxoSmithKline) No 10–40 mg/day 8.8
Sertraline (Zoloft®, Pﬁ  zer) No 25–200 mg/day 4.1
Fluoxetine (Prozac®, Lilly) No 5–20 mg/day 3.9
Serotonergic tricyclic antidressant
Clomipramine (Anafranil®, Ciba Geigy) No 25–50 mg/day 4.6
Ejaculation speciﬁ  c selective serotonin 
reuptake inhibitors (ESSRIs)
Dapoxetine (Johnson & Johnson) Phase 3 studies 30–60 mg 
1–3 hours prior to 
intercourse
3.0–3.6
UK-390,957 (Pﬁ  zer) Phase 2 studies NA NA
Placebo – – 1.4Neuropsychiatric Disease and Treatment 2006:2(4) 501
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Future of PE drug development
Several in vitro and animal studies have demonstrated that 
the desensitization of 5-HT1A receptors, increased activation 
of postsynaptic 5-HT2C receptors, and the resultant higher 
increase in synaptic 5-HT neurotransmission seen in daily dos-
ing of SSRI class drugs can be acutely achieved by blockade of 
these receptors by administration of an on-demand SSRI and a 
5-HT1A receptor antagonist (Cremers et al 2000; Williamson 
et al 2003; de Jong et al 2005). Drug combinations such as this 
or single agents that target multiple receptors may form the 
foundation of more effective future on-demand medication.
Conclusion
The off-label use of SSRIs and clomipramine, along with the 
development of new on-demand drugs for the treatment of PE, 
has drawn new attention to this common and often ignored sex-
ual problem. Recent epidemiological and observational research 
has provided new insights into the problem and the associated 
negative psychosocial effects of this dysfunction. However, 
until the neurobiological, physiological, and psychological 
mechanisms responsible for PE are better understood, ideal 
treatment outcomes may remain elusive. Ejaculation-speciﬁ  c 
selective serotonin reuptake inhibitors such as dapoxetine and 
UK-390,957 represent a major development in sexual medicine, 
and offer patients the convenience of on-demand dosing, 
signiﬁ  cant improvements in IELT, ejaculatory control, and 
sexual satisfaction with minimal adverse effects. Drug combina-
tions or single agents that target multiple 5-HT receptors may 
represent the next stage of PE drug development.
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